Kanak Kanti

Kanak Kanti


Recent articles

Is This Regeneron's Biggest Opportunity?

Alirocumab represents a long-term opportunity to Regeneron and its partner Sanofi.

Why This Acquisition Makes Sense

Mesoblast's acquisition of Osiris Therapeutics' MSC business makes strategic sense.

A Solid Health Care Stock to Watch?

With its solid business, Baxter International is a stock to watch for investors looking for dividends.

This Company Is Focused on Delivering Value to Patients and Shareholders

Dyax is looking to capitalize on its unique phage display technology (companies discussed in this article include VPHM, SHPG, DYAX).

Why AbbVie's Global Alliance With Galapagos Is Good News for Investors

AbbVie's global alliance with Galapagos will further boost the company's financial performance.

Alnylam's Biggest Opportunities

Alnylam Pharmaceuticals is an emerging leader in a new gene-based therapy.

3 Stocks to Watch in the Urology Devices Market

How Endo Health is performing in the urology devices market.

Abraxane's Approval for Pancreatic Cancer Is a Major Milestone for Celgene

Abraxane approval for pancreatic cancer will boost Celgene's top-line.

Why You Should Get Excited About This Health Care Company

Steris offers steady growth in multiple markets.

Why Teva's Generic Version of Xeloda Has Significant Potential

Teva's generic Xeloda may be a game changer for the company.

An Excellent Investment in the Biotech Space?

Exelixis might be a stock to watch.

4 Reasons to Buy This Biotechnology Stock

Isis has many positives for investors.

Time to Bet on This Biotech Spinoff?

Theravance is not too healthy right now.

Will History Repeat for Inhaled Insulin?

Mannkind's Afrezza is better than Exubera, but by how much?


3 Justifications for the High Cost of Gattex

Gattex may seem pricey, but it will still sell.

What Does Roche's Inovio Deal Mean for Investors?

Inovio is not for the short-sighted.

Cheers and Jeers for Amgen's Pipeline

Amgen's heart drug may be revived, despite failure, all puns intended.

Everyone Wants a Piece of This Mega-Blockbuster

The fight for sofosbuvir.

3 Reasons to Like This Critical Care Company

A few reasons why The Medicines Company is investment grade.

Outsourcing Your Laboratory

Covance is doing well with its contract research business.